Equity Profile

ABBV

AbbVie Inc.

Health CareBiotechnology$399.3B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

AbbVie Inc. is a major player in the biotechnology sector, focusing on developing advanced therapies for complex diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well AbbVie is managing costs and generating income.

N/A

Revenue Growth

Revenue growth will provide insight into the demand for AbbVie's products and the effectiveness of its sales strategies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ABBV Q2-2026 Earnings Preview

Context

Company Snapshot

AbbVie Inc. is a major player in the biotechnology sector, focusing on developing advanced therapies for complex diseases. With a market cap of $385 billion, the company is known for its innovative treatments and strong presence in the healthcare industry, which is increasingly important as global healthcare needs evolve.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.22%

Avg Stock Reaction

+1.54%

Last Quarter Recap

In Q1 2026, AbbVie reported an EPS of $2.65, slightly beating expectations. The stock reacted positively, gaining 3.14% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about AbbVie's upcoming earnings, given its strong track record of beating EPS estimates in recent quarters.

Bull Case

If AbbVie continues its trend of beating EPS estimates and shows strong revenue growth, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could result in a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

EPS is a crucial metric for assessing profitability and will heavily influence investor sentiment.

What updates will be provided on the drug pipeline?

Insights into pipeline developments can significantly affect future revenue expectations and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating AbbVie's potential for pipeline success, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

AbbVie has consistently beaten EPS estimates in 88% of the last eight quarters, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting that investors expect significant news.

Recent performance trends show that AbbVie has been able to navigate competitive pressures effectively.

Key Risk

If pipeline updates reveal significant advancements, it could lead to a re-evaluation of AbbVie's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating AbbVie's ability to maintain its earnings momentum amid competitive pressures and pipeline developments.

Bull Confirmed If

An EPS of $2.70 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $2.60 would confirm the bear case, suggesting potential challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.85%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±5.8% while ABBV has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

23.2%

Calls (444K)P/C Ratio: 0.73Puts (307K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AbbVie beats expectations, history suggests a positive reaction with an average 1-day move of +1.78%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline, with history suggesting an average 1-day move of -0.15%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-TXJulie JohnsonRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the drug pipeline and upcoming launches.
2Details on revenue growth from key products.
3Insights into cost management and operational efficiency.
4Updates on competitive landscape and market share.
5Guidance for the upcoming quarters and any changes in strategy.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

AbbVie Inc. is a major player in the biotechnology sector, focusing on developing advanced therapies for complex diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well AbbVie is managing costs and generating income.

N/A

Revenue Growth

Revenue growth will provide insight into the demand for AbbVie's products and the effectiveness of its sales strategies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ABBV Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.22%

Avg Stock Reaction

+1.54%

Last Quarter Recap

In Q1 2026, AbbVie reported an EPS of $2.65, slightly beating expectations. The stock reacted positively, gaining 3.14% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about AbbVie's upcoming earnings, given its strong track record of beating EPS estimates in recent quarters.

Bull Case

If AbbVie continues its trend of beating EPS estimates and shows strong revenue growth, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could result in a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

EPS is a crucial metric for assessing profitability and will heavily influence investor sentiment.

What updates will be provided on the drug pipeline?

Insights into pipeline developments can significantly affect future revenue expectations and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating AbbVie's potential for pipeline success, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

AbbVie has consistently beaten EPS estimates in 88% of the last eight quarters, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting that investors expect significant news.

Recent performance trends show that AbbVie has been able to navigate competitive pressures effectively.

Key Risk

If pipeline updates reveal significant advancements, it could lead to a re-evaluation of AbbVie's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating AbbVie's ability to maintain its earnings momentum amid competitive pressures and pipeline developments.

Bull Confirmed If

An EPS of $2.70 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $2.60 would confirm the bear case, suggesting potential challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.85%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±5.8% while ABBV has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

23.2%

Calls (444K)P/C Ratio: 0.73Puts (307K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AbbVie beats expectations, history suggests a positive reaction with an average 1-day move of +1.78%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline, with history suggesting an average 1-day move of -0.15%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-TXJulie JohnsonRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the drug pipeline and upcoming launches.
2Details on revenue growth from key products.
3Insights into cost management and operational efficiency.
4Updates on competitive landscape and market share.
5Guidance for the upcoming quarters and any changes in strategy.